You are currently viewing The Nile Dedicated Bifurcation Stent: Long-Term Results and Technology Advancement

The Nile Dedicated Bifurcation Stent: Long-Term Results and Technology Advancement

EBC - ON DEMAND

European Bifurcation Club 2014 – EBC 2014 – Bordeaux, France

At last randomized trials with dedicated bifurcation stents!

The Nile Dedicated Bifurcation Stent: Long-Term Results and Technology Advancement

Author: Gregory Pavlides, MD, PhD, Director, Cardiac Cath Labs & Interv Cardiology, University of Nebraska Medical Center, Omaha, NE, USA

 

CONCLUSION

  • Preliminary results with the novel Nile SIRtechnology, incorporating the Nile dedicated bifurcation pladorm with a biodegradable PLA polymer as drug-carrier, and sirolimus as antiproliferative agent, demonstrated favorable results in the treatment of complex bifurcation lesions, including high angiographic and procedural success and safety
  • Initial assessment of efficacy at 6 months follow-up showed high efficacy in inhibi-ng neoin-mal hyperplasia within the bifurcation anatomy, as demonstrated by the relatively low late lumen loss – a surrogate of neointimal hyperplasia, comparable to the current best- in-class “limus” devices
  • Results from ongoing registry expected in order to confirm these promising results

 

Download here

Leave a Reply